Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia. - Wikidata - wikimedia - TriplyDB

Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia.

Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia.

http://www.wikidata.org/entity/Q35082380

about

Antipsychotic Polypharmacy and Corrected QT Interval: A Systematic Review Safety and tolerability of antipsychotic polypharmacy.Ziprasidone as adjunctive therapy in severe bipolar patients treated with clozapine.

P2860

Q26801835-829ADAE6-FC66-4511-B459-F9D959A62885 Q36062421-D0FF51DC-2FE9-4FD6-8B06-8A04FF6F73D2 Q39037156-00ED3320-F8A3-4BC8-9833-7C9200411120

P2860

Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia.

http://www.wikidata.org/entity/Q35082380

description

2009 nî lūn-bûn

@nan

2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Ziprasidone as an adjuvant for ...... dity in chronic schizophrenia.

@ast

Ziprasidone as an adjuvant for ...... dity in chronic schizophrenia.

@en

type

label

Ziprasidone as an adjuvant for ...... dity in chronic schizophrenia.

@ast

Ziprasidone as an adjuvant for ...... dity in chronic schizophrenia.

@en

prefLabel

Ziprasidone as an adjuvant for ...... dity in chronic schizophrenia.

@ast

Ziprasidone as an adjuvant for ...... dity in chronic schizophrenia.

@en

P1433

Q35082380-C9B9A698-76BB-4361-A772-5C08DD5C8745

P1476

Q35082380-861586BD-3F04-49A9-A119-3C079F072B5D

P2093

Q35082380-0C00DCA2-0CF4-4E87-A271-3BC2CC922701

Q35082380-0FE72745-3D45-4C9C-9A68-B73BEEFE5AC2

Q35082380-1350172F-F765-42F3-B160-302A05D8C20F

Q35082380-2FA09EC2-EACC-4D54-96BB-433250E36057

Q35082380-393DCD69-DDEF-44B6-A62F-E46E1893FF65

Q35082380-3A080CB4-9D84-4D5D-A018-904C63F2A152

Q35082380-476431DF-69D0-4953-A50A-3B646BE6B6B0

Q35082380-5C1515DC-28C8-4D2F-92EB-13A28ACC5D7B

Q35082380-6287DD09-9944-4AE2-AEBE-A0387B2261B8

Q35082380-A759BB51-EC89-4852-BDAD-A513D821B6E1

P2860

Q35082380-09490747-850E-488E-93B5-3A4C6A8C2282

Q35082380-170F648E-8749-4182-9460-65FBC64CF3B9

Q35082380-18E5A173-A711-4F97-B03A-A2B5C6D7157B

Q35082380-1C4D2944-A3A6-4E8B-959D-B21C40506C24

Q35082380-269501AD-5B86-468C-BDB1-F536C920360B

Q35082380-27925C85-E124-4ABD-A36A-D56EC985891A

Q35082380-296226B2-76B7-4E5F-AE49-430D3C6C4F2B

Q35082380-29FE85D3-4DF0-4393-B00D-286C8E80F20B

Q35082380-2BBD3D23-F808-4E73-ABBB-E4CC66ED22ED

Q35082380-333738D7-F2D1-4CC6-B4A4-FC3C43642304

P304

Q35082380-45E570F9-96E6-43CA-BD5B-A59D2694989E

P31

Q35082380-2CA6A1FB-A969-4B5A-915A-B16FBADA5117

P356

Q35082380-2D878E11-68BA-4B99-AD57-4C393A1897D8

P433

Q35082380-22F3A761-EF06-4CEC-AA47-113942D8F3D6

P478

Q35082380-5A0FC618-A6C8-48DC-BC50-C527379F6E8F

P50

Q35082380-454DB40B-1E7D-4B8B-B68E-463403549CAA

P577

Q35082380-FCC02EF6-64BB-4E84-B36F-DFDF1D7914B7

P5875

Q35082380-12F541DB-E747-4999-BCFB-2EBC0E3006AB

P698

Q35082380-69394331-02F1-463B-A740-245F066AA1A9

P921

Q35082380-97191E70-0D18-4A49-9F2B-922546993D72

P932

Q35082380-2060FFF6-2F02-4462-AC7F-B2DEA09EFDC5

P356

P1433

Human Psychopharmacology

P1476

Ziprasidone as an adjuvant for ...... dity in chronic schizophrenia.

@en

P2093

Anne E Evins

http://www.w3.org/2001/XMLSchema#string

Bikash Sharma

http://www.w3.org/2001/XMLSchema#string

Christina P Borba

http://www.w3.org/2001/XMLSchema#string

Corrine Cather

http://www.w3.org/2001/XMLSchema#string

David C Henderson

http://www.w3.org/2001/XMLSchema#string

Kate Miley

http://www.w3.org/2001/XMLSchema#string

Oliver Freudenreich

http://www.w3.org/2001/XMLSchema#string

Paul M Copeland

http://www.w3.org/2001/XMLSchema#string

Ryan Boxill

http://www.w3.org/2001/XMLSchema#string

Sharon I Forstbauer

http://www.w3.org/2001/XMLSchema#string

P2860

Antipsychotic-induced weight gain: a comprehensive research synthesis

Bodyweight gain with atypical antipsychotics. A comparative review.

Ziprasidone: comprehensive overview and clinical use of a novel antipsychotic.

H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.

Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.

Olanzapine-associated diabetes mellitus.

Olanzapine-associated severe hyperglycemia, ketonuria, and acidosis: case report and review of literature.

Antipsychotic medication: effects on regulation of glucose and lipids.

Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia.

Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database.

P304

225-232

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HUP.1012

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24198536

http://www.w3.org/2001/XMLSchema#string

P698

19283774

http://www.w3.org/2001/XMLSchema#string

P921

P932

4327763

http://www.w3.org/2001/XMLSchema#string